Navigation Links
Hospira to Present at the 2008 Annual Credit Suisse Health Care Conference on November 12
Date:11/4/2008

LAKE FOREST, Ill., Nov. 4 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical and medication delivery company, today announced that Christopher B. Begley, chairman and chief executive officer, and Thomas E. Werner, senior vice president, Finance, and chief financial officer, will make a formal presentation at the 2008 Annual Credit Suisse Health Care Conference on Wednesday, Nov. 12, 2008, in Phoenix.

The presentation is scheduled to begin at noon Mountain time on Wednesday, Nov. 12, 2008. It will be available to all interested parties through a live audiocast accessible via the investor relations section of Hospira's Web site at http://www.hospirainvestor.com. Listeners should log on approximately 10 minutes in advance to ensure proper computer setup to receive the audiocast. The slides accompanying the presentation will be available on the Hospira Web site. A replay of the webcast will be available on the Hospira Web site approximately 24 hours after the live presentation.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has more than 14,000 employees. Learn more at http://www.hospira.com.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. FDA Approves New Indication for Hospiras Precedex (Dexmedetomidine HCL) Injection
2. Hospira Announces New Contracts With Premier Purchasing Partners for Infusion Devices, Solutions And Equipment
3. Hospira Reports Second-Quarter 2008 Results
4. Hospira Hosts Conference Call for Second-Quarter 2008 Earnings
5. Hospira Highlights Strategic Initiatives at Its 2008 Annual Meeting of Shareholders
6. Hospira to Present at the Bank of America 2008 Health Care Conference on May 14
7. Hospira Acquires Sculptor
8. Hospira Hosts Conference Call for First-Quarter 2008 Earnings
9. Hospira to Present at the Bear Stearns 10th Annual London Healthcare Conference on March 13
10. Hospira Reports Fourth-Quarter and Full-Year 2007 Results
11. Hospira Launches Generic Irinotecan Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... (PRWEB) December 25, 2014 Parker & ... outstanding customer service and affordable quality regarding heating, cooling ... announces recognition in 2014 by the “Queen of Clean” ... has earned an impressive reputation over the years for ... a wide range of contractor services for both homeowners ...
(Date:12/24/2014)... Epigenetics finds applications in a large number of fields ... biology, and research for metabolic and genetic disorders. It ... used techniques for the discovery and development of cancer ... rapidly growing worldwide. In 2012, there were 14.1 million ... million people living with cancer (within five years of ...
(Date:12/24/2014)... December 24, 2014 Risperdal lawsuit ( ... mass tort litigation currently underway in Pennsylvania’s Philadelphia Court ... of December 24, 2014, court documents indicate that 1,183 ... of individuals who developed gynecomastia (male breast growth) and ... the Court indicates that this represents an increase of ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 The ... that allege the blood thinner caused life-threatening episodes ... a leadership structure for the proceeding, Bernstein Liebhard ... 17th, the Court plans to select lawyers to ... also plans on appointing a Plaintiffs’ Steering Committee, ...
(Date:12/24/2014)... TX (PRWEB) December 25, 2014 The ... to 2023” focuses on the current treatment landscape, unmet ... cancer market. Stivarga is a drug which is used ... drug is orally administered and is also prescribed to ... drug which is FDA approved is a multi-kinase inhibitor ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... is Leading Proponent for Single-Payer Healthcare ... Reforms - ,Medicare ... camera on the,fastest-growing union in America -- and the nation,s ... California Nurses,Association/National Nurses Organizing Committee,s fight for guaranteed,single-payer healthcare in ...
... odds of heart attack, death, study finds , , THURSDAY, May ... can hear when passing a stethoscope over a main artery ... attack and death from heart disease and stroke, a new ... (pronounced brew-ee) -- is caused by turbulent blood flow due ...
... 6, 2008) The American Society of Hematology (ASH) ... for its 2008 Minority Medical Student Award Program (MMSAP), ... in hematology research. Under the program, each award recipient ... a career development mentor, travel stipends to attend medical ...
... $0.18 In Line with Previously Announced ... Expectations, ... largest air medical transportation company in the,world, reported financial results for the ... flight volumes. For the quarter,revenue increased 45.0% to $118.1 million from $81.5 ...
... Corporation is launching a,third dental industry-focused online Tradeshow, ... is now open and available at, http://www.ddstechfair.com . ... bring dental professionals together with,colleagues and manufacturers at ... Tech Fair is designed to give the dental ...
... role in development of defective cells in type 2 diabetics ... an important gene during fetal development appears to increase vulnerability ... , Intrauterine growth retardation (IUGR), which causes low birth ... type 2 diabetes and other diseases when a child grows ...
Cached Medicine News:Health News:Bill Moyers' Journal to Feature California Nurses Association/National Nurses Organizing Committee in Friday, May 9th Episode 2Health News:Noise in Artery Could Warn of Heart Risk 2Health News:Minority medical students receive support to increase diversity in hematology 2Health News:Air Methods Reports 1Q2008 Results and 2Q2008 Update 2Health News:Air Methods Reports 1Q2008 Results and 2Q2008 Update 3Health News:Air Methods Reports 1Q2008 Results and 2Q2008 Update 4Health News:Air Methods Reports 1Q2008 Results and 2Q2008 Update 5Health News:Air Methods Reports 1Q2008 Results and 2Q2008 Update 6Health News:PennWell Announces DDS Tech Fair 2Health News:Fetal Gene May Contribute to Diabetes Risk 2
(Date:12/24/2014)... , December 24, 2014 ... on Global Disposable Syringe Industry of 178 ... online business intelligence library. The ... Syringe Industry is a professional and deep ...  For overview analysis, the report introduces Disposable ...
(Date:12/24/2014)... 2014 Tianyin Pharmaceutical Co., Inc. (NYSE ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... that the Company achieved the Public Notice (Gong ... certificate of TPI,s Qionglai Facility (QLF) from the ... notice period is a significant procedure of GMP ...
(Date:12/22/2014)... Mass. , Dec. 22, 2014 ... leading manufacturer of innovative dialysis products, announced today ... has cleared its System One™ to perform hemodialysis ... known as home nocturnal hemodialysis. NxStage,s® System One ... by the FDA for this indication. ...
Breaking Medicine Technology:World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3
... - First of three ongoing randomized chemotherapy combination trials ... HGS-ETR1 in the treatment of specific cancers -, ... HGSI ) today reported initial topline results from,an ... receptor antibody,HGS-ETR1 (mapatumumab) in combination with bortezomib (Velcade) in ...
... This Common and Successful Surgery, ROCHESTER, Minn., ... issue of Mayo Clinic Health Letter. You may,cite ... is allowed for a,fee. Mayo Clinic Health Letter ... your editorial policies permit: Visit, http://www.HealthLetter.MayoClinic.com or ...
Cached Medicine Technology:Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma 2Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma 3Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma 4Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma 5Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma 6September 2008 Mayo Clinic Health Letter Highlights Cataract Removal, Severe Headache and Dual Energy X-Ray Imaging 2September 2008 Mayo Clinic Health Letter Highlights Cataract Removal, Severe Headache and Dual Energy X-Ray Imaging 3September 2008 Mayo Clinic Health Letter Highlights Cataract Removal, Severe Headache and Dual Energy X-Ray Imaging 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: